19/11/2001
London, UK – 19 November 2001: ReGen Therapeutics Plc (the ‘Company’) announces that, further to its announcement of 30 October 2001, Georgiades Biotech Limited, a subsidiary of the Company, has now completed the transfer to it of the remaining intellectual property rights relating to Colostrinin™, the Company’s potential treatment for Alzheimer’s disease which it is currently developing.
For further information, please contact:
Lisa Baderoon
BUCHANAN COMMUNICATIONS
Tel: 020 7466 5000 or M: 07721 413496
lisab@buchanan.uk.com